Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1)

Abstract

The results of this clinical Phase II study demonstrate that the combination of paclitaxel-based therapy causes complete remissions previously not obtained with second-line chemotherapy, although no conclusions can be drawn as to the effectiveness of the individual substances. Further trials have to be evaluated with regard to the individual components.